Search
Vanoxerine
go.drugbank.com/drugs/DB03701InvestigationalIt was synthesized in the late 1970s and developed as a potential treatment for depression. … [A248555] Vanoxerine is an investigational drug and has not been approved for therapeutic use.
Plerixafor
go.drugbank.com/drugs/DB06809ApprovedInvestigationalSince CXCR4 and SDF-1α are involved in the trafficking and homing of CD34+ cells to the marrow compartment, blocking this interaction leads to an increase in CD34+ cell circulating levels. … [A7115] Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.[A7117,L45678]
Durvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigationalsmall cell lung cancer (ES-SCLC). … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in
Lecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023. … [A253947,A253957] In clinical trials, it significantly reduced brain Aβ plaques compared to placebo.
CCX915
go.drugbank.com/drugs/DB05159ExperimentalCCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigational[A1499] Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form. … [A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency.
International brands: Nu-MedopaProducts: Nu-medopa Tab 250mg, Nu-medopa Tab 500mgDaratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigationalIn July 2024, it was further approved in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in newly diagnosed, transplant-eligible patients. … [A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
ACR-16
go.drugbank.com/drugs/DB05371InvestigationalACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington … ACR-16 is also being studied in other psychiatric and neurologic diseases.
Zoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigationalGonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance. … FDA in December 2025, following Fast Track, Qualified Infectious Disease Product, and Priority Review designations.[L54743,L54803]
Ublituximab
go.drugbank.com/drugs/DB11850ApprovedInvestigationalCD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions. … (ADCC), mediated by interactions between an antibody and Fcγ receptors on natural killer cells or macrophages.